Aptamer-mediated hollow MnO2 for targeting the delivery of sorafenib. (31st December 2023)

• Record Type: Journal Article
• Authors: Wang, Ziyue; Wu, Cuicui; Liu, Jinren; Hu, Shunxin; Yu, Junli; Yin, Qiangqiamg; Tian, Hongda; Ding, Zhipeng; Qi, Guiqiang; Wang, Li; Hao, Liguo
• Is Part Of: Drug delivery. Volume 30:Number 1(2023)
• Page Start: 28
• Page End: 39
• Publication Date: 2023-12-31
• Subjects: Hollow mesoporous MnO2 -- drug delivery system -- HCC -- MR imaging; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2022.2149897
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Sorafenib (SRF) presents undesirable effects in clinical treatment, due to the lack of targeting, poor water solubility, and obvious side effects. In this study, we constructed a novel nanodrug carrier system for accurate and efficient delivery of SRF, improving its therapeutic effects and achieving tumor-specific imaging. The hollow mesoporous MnO2 (H-MnO2 ) nanoparticles equipped with target substance aptamers (APT) on the surface were used to load SRF for the first time. The resulting H-MnO2 -SRF-APT could specifically bound to glypican-3 (GPC3) receptors on the surface of hepatocellular carcinoma (HCC), rapidly undergoing subsequent degradation under decreased pH conditions in the tumor microenvironment (TME) and releasing the loaded SRF. In this process, Mn 2+ ions were used for T1 -weighted magnetic resonance imaging simultaneously. The in vitro cell experiments indicated that H-MnO2 -SRF-APT showed much more effects on the inhibition in the proliferation of Huh7 and HepG2 HCC cells than that of the non-targeted H-MnO2 -SRF and free SRF. Besides, the in vivo results further confirmed that H-MnO2 -SRF-APT could effectively inhibit the growth of xenograft tumors Huh7 in the naked mouse with good biosafety. In conclusion, H-MnO2 -SRF-APT could significantly enhance the therapeutic effect of SRF and is expected to be a new way of diagnosis and treatment of HCC.